QUICK READ: The Federal Drug Administration’s Office of Prescription Drug Promotion (OPDP) on Wednesday issued the first warning letter specific to paid-search ads since 2014. The FDA said that the search results did not include any fair balance. This is an example of how out of date the FDA’s Office of Prescription Drug Promotion (OPDP) really is.

SUMMARY: Once again the media is failing to do its job when it comes to reporting on privacy issues around the Google acquisition of Fitbit. The reality is that the data does not have personally identifiable data such as name, age and street address. Adlucent research found that consumers crave a personalized advertising experience and that 71% of respondents prefer ads tailored to interests and shopping habits. But do consumers understand what data is actually collected?

KEY TAKEAWAY:[inlinetweet prefix=”” tweeter=”” suffix=””]Today’s online ads are not about getting in front of as many people as you can[/inlinetweet], they are about getting relevant ads in front of highly targeted people. This is especially true for pharma clients who are marketing specialty drugs and who don’t want their ads appearing on controversial sites.

Small-Ad-Agency-AdvantageAccording to McKinsey Global Survey results executives most often attribute the success of digital programs to managerial factors—senior management’s interest and attention, internal leadership, good program management, and alignment between organizational structure and goals— and are less likely to cite any technical considerations.  In fact, across most of the C-suite, larger shares of respondents report that their companies’ senior executives are now supporting and getting involved in digital initiatives.  However, this is an area where pharma still lags badly.